Following a security review, the Pharmacovigilance Possibility Evaluation Committee (PRAC) of the European Medicines Agency (EMA) has suggested adding sinus bradycardia to the product designate…
Following a security review, the Pharmacovigilance Possibility Evaluation Committee (PRAC) of the European Medicines Agency (EMA) has suggested adding sinus bradycardia to the product designate…